Research programme: cardiosphere-derived stem cell therapeutics - Capricor Therapeutics

Drug Profile

Research programme: cardiosphere-derived stem cell therapeutics - Capricor Therapeutics

Alternative Names: CDC therapeutics - Capricor; CPI-002; CPI-004; CPI-005

Latest Information Update: 31 Dec 2013

Price : $50

At a glance

  • Originator Capricor
  • Developer Capricor Therapeutics; Cedars-Sinai Health System; Johns Hopkins University School of Medicine
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chronic heart failure; Myocardial infarction

Most Recent Events

  • 31 Dec 2013 Preclinical development is ongoing in USA
  • 21 Nov 2013 Nile Therapeutics has merged with Capricor to form Capricor Therapeutics
  • 20 Oct 2009 Preclinical trials in Chronic heart failure in USA (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top